Cryopreservation of hematopoietic stem cell grafts has become more widely adopted. The impact of cryopreservation on clinical outcomes remains ambiguous, with existing studies limited by retrospective...

Post-transplant cyclophosphamide (PTCy) has transformed graft-versus-host disease (GVHD) prophylaxis but its role in matched-donor reduced-intensity allogeneic hematopoietic cell transplantation (allo...

BACKGROUND: Graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic cell transplantation (HCT). Systemic corticosteroids, the standard treatment for GVHD, inc...

Axatilimab did not slow FVC decline in idiopathic pulmonary fibrosis, but Syndax says its cGVHD programme remains on track.

Allogeneic transplants can trigger graft-versus-host disease and graft rejection. Lopes Souza et al. demonstrate that deletion of Ctps1 in T cells prevents GVHD and reduces skin rejection. Furthermore, pharmacological inhibition of CTPS1 improves survival in acute GVHD, highlighting CTPS1 as a promising therapeutic target for alloreactive T cell responses.

Large-scale longitudinal analysis of posttransplant immune reconstitution reveals how T cell–directed immunosuppression shapes transplant outcomes.

A higher-dose anti-CD25 regimen without methotrexate lowered acute GVHD rates and improved survival in patients undergoing haploidentical transplant.

Extracorporeal photopheresis (ECP) is an immunosuppressive therapy with long-established indications for treating T cell-mediated diseases, including steroid-refractory, acute or chronic graft-versus-host disease (GVHD), cutaneous T-cell lymphoma (CTCL) and chronic rejection after heart or lung transplantation1,2. The ECP procedure involves collecting autologous peripheral blood leucocytes by leukapheresis, which are separated from erythrocytes and platelets, then returned to patients. Passage of leucocytes through the extracorporeal circuit induces cellular activation, release of soluble mediators and metabolic products, modification of plasma proteins and fragmentation of physically damaged cells3,4. The resulting leucocyte concentrates are then incubated with a DNA-intercalating agent, 8-methoxypsoralen (8-MOP), before exposure to ultraviolet A (UVA) irradiation. In the THERAKOS™ CELLEX™ Photopheresis System, these steps are performed within the integrated, online system as part of a single clinical procedure, whereas in offline ECP systems, the collected leucocytes are transferred to separate devices for UVA irradiation5. Excitation of 8-MOP bound to DNA with UVA causes double-stranded breaks, which initiate apoptosis6. Thus, ECP results in a heterogeneous cell suspension in autologous plasma, which consists of mixed leucocyte types at various stages of apoptotic and non-apoptotic cell death. There is an emerging consensus that ECP acts primarily through mononuclear phagocytes that are driven to a tolerogenic...

Extracorporeal photopheresis (ECP) is an immunosuppressive therapy with long-established indications for treating T cell-mediated diseases, including steroid-refractory, acute or chronic graft-versus-host disease (GVHD), cutaneous T-cell lymphoma (CTCL) and chronic rejection after heart or lung transplantation1,2. The ECP procedure involves collecting autologous peripheral blood leucocytes by leukapheresis, which are separated from erythrocytes and platelets, then returned to patients. Passage of leucocytes through the extracorporeal circuit induces cellular activation, release of soluble mediators and metabolic products, modification of plasma proteins and fragmentation of physically damaged cells3,4. The resulting leucocyte concentrates are then incubated with a DNA-intercalating agent, 8-methoxypsoralen (8-MOP), before exposure to ultraviolet A (UVA) irradiation. In the THERAKOS™ CELLEX™ Photopheresis System, these steps are performed within the integrated, online system as part of a single clinical procedure, whereas in offline ECP systems, the collected leucocytes are transferred to separate devices for UVA irradiation5. Excitation of 8-MOP bound to DNA with UVA causes double-stranded breaks, which initiate apoptosis6. Thus, ECP results in a heterogeneous cell suspension in autologous plasma, which consists of mixed leucocyte types at various stages of apoptotic and non-apoptotic cell death. There is an emerging consensus that ECP acts primarily through mononuclear phagocytes that are driven to a tolerogenic...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Read the full paper: Inhibition of the CTP synthase 1 prevents GVHD and delays skin graft rejection revealing distinct alloreactive T cell responses

The GVHD Treatment Market was valued at US$ 2.14 billion in 2025 and is projected to reach US$ 4.60 billion by 2033, expanding at a CAGR of 10.04% from 2026 to 2033. Market growth is supported by increasing hematopoietic stem cell transplantation procedures, rising adoption of biologics and targeted therapies, and continued advances in immunotherapy research. The market is also gaining opportunities from personalized treatment strategies, biomarker-based patient selection, emerging healthcare markets, and innovative cellular therapies.

Ruxolitinib 1.5% cream outperformed placebo vehicle in reducing lesional skin involvement in patients with epidermal or superficially sclerotic cutaneous chronic GVHD.

Allogeneic hematopoietic cell transplantation (allo-HCT) hinges on a delicate trade-off between graft-versus-tumor control and graft-versus-host disease (GvHD), mediated by donor T-cell recognition of...